Clearmind Medicine (CMND) said Thursday that the Macau International Intellectual Property Office has granted a patent for its binge behavior treatment.
The patent is directed to be used a a primary amine aminoindan compound for binge behavior regulation, including such compounds beyond its psychedelic molecule, 5-methoxy-2-aminoindan.
Shares of Clearmind Medicine were up over 7% in premarket activity Thursday.
Price: 1.48, Change: +0.10, Percent Change: +7.25
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.